Shots:

• BMS to get non-exclusive access to Xencor’s Xtend Fc technology to extend the half-life of a novel Ab combination therapy that is intended to neutralize the SARS-CoV-2 virus to prevent COVID-19
• BMS will solely lead research- development- regulatory and commercial activities for SARS-CoV-2 mAb Duo. Xencor is eligible to receive royalties from the sales of products including Abs
• P-I study will assess dosing and safety of the SARS-CoV-2 mAb Duo- discovered by investigators at Rockefeller University Hospital- while the P-II & P-III studies are being planned as part of the NIH ACTIV-2 trial examining the treatment of infected outpatients

  Ref: Businesswire | Image: Xencor